Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Alpha IVF reported a net profit of RM12 million, down about 20.5% from RM15.1 million last year, while revenue climbed 9.4% to RM47.3 million. The dip in profit was mainly due to pre-operational costs from its ongoing expansion. Still, the company is declaring a first interim dividend of half a sen per share
Financial Snapshot (Q2 2025 vs. Q2 2024)
-Revenue: RM 47.3 Million (Up 9.4% from RM 43.2M)
-Profit After Tax (PAT): RM 11.85 Million (Down from RM 15.3M)
-Dividend Declared: 0.50 sen per share (Totaling RM 24.3 Million)
-Half-Year Revenue: RM 99.4 Million (A strong 15.3% year-on-year increase)
Profits were slightly lower compared to last year primarily because the company is investing heavily in future growth. High "pre-operational costs" for new centers are currently being absorbed to pave the way for long-term dominance.
The Malaysia Year of Medical Tourism (MYMT) 2026 is seen as a supportive catalyst for the local healthcare sector. With MYMT 2026, Malaysia is setting its sights on achieving about RM12bil in healthcare revenue by 2030. Alpha will be capitalize big on this.
Alpha IVF targets North Sumatra with new Medan satellite clinic
Fertility care specialist Alpha IVF Group Bhd has launched its Medan Satellite Clinic, marking its third presence in Indonesia after Jakarta and Surabaya.
In a statement on Monday, the group said the Medan expansion strengthens its regional patient acquisition and referral strategy by extending its front-end presence into North Sumatra, one of Indonesia’s most populous regions.
Based on its revenue exposure to health tourism in Malaysia, HLIB Research noted that Alpha IVF Group Bhd has clearly emerged as the primary beneficiary, given its outsized exposure.
Yeah, HLIB's got a point there; Alpha IVF seems to be in a prime position to capitalize on the health tourism trend in Malaysia due to their significant focus. It's definitely a factor worth watching for anyone considering their stock.